128 related articles for article (PubMed ID: 7499447)
1. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha.
Canobbio L; Rubagotti A; Miglietta L; Cannata D; Curotto A; Amoroso D; Boccardo F
J Cancer Res Clin Oncol; 1995; 121(12):753-6. PubMed ID: 7499447
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
van Herpen CM; De Mulder PH
Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha.
Fosså SD; Kramar A; Droz JP
Eur J Cancer; 1994; 30A(9):1310-4. PubMed ID: 7999419
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha and survival in renal cell cancer.
Fossa S; Jones M; Johnson P; Joffe J; Holdener E; Elson P; Ritchie A; Selby P
Br J Urol; 1995 Sep; 76(3):286-90. PubMed ID: 7551834
[TBL] [Abstract][Full Text] [Related]
8. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
[TBL] [Abstract][Full Text] [Related]
9. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
[TBL] [Abstract][Full Text] [Related]
10. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).
Pandha H
Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872
[No Abstract] [Full Text] [Related]
11. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
[TBL] [Abstract][Full Text] [Related]
15. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapeutic treatment for metastatic renal carcinoma].
Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
[TBL] [Abstract][Full Text] [Related]
18. Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?
Oliver RT
Br J Cancer; 1998 Apr; 77(8):1318-20. PubMed ID: 9579839
[No Abstract] [Full Text] [Related]
19. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
20. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis.
Jones M; Philip T; Palmer P; von der Maase H; Vinke J; Elson P; Franks CR; Selby P
Cancer Biother; 1993; 8(4):275-88. PubMed ID: 7804369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]